First generic #remdesivir will be sold by #Bangladesh drug maker
▻https://www.statnews.com/pharmalot/2020/05/22/gilead-remdesivir-covid19-coronavirus-beximco-patent
Un règlement de l’#OMC permet aux pays « moins développés » de produire (et même de l’exporter semble-t-il) une version #générique d’un nouveau médicament sans autorisation préalable du détenteur du #brevet ni expiration de ce dernier,
Beximco [Bangladesh Export Import Company] Pharmaceuticals is donating copies of the Gilead Sciences (GILD) medicine to state-run hospitals free of charge, but will sell the intravenous treatment to private clinics. Moreover, the company is reportedly willing to export its version if other governments request the drug, although it does not have a license from Gilead to do so.
Beximco is able to take this step under provisions of a World Trade Organization agreement, which permits a “least-developed” country to grant a public agency or a company a license to copy a patented medicine without the consent of the patent holder. As a result, Bangladesh is not required to grant pharmaceutical patents until 2033.
